The Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford University Medical Center offers a specialty program dedicated to the needs of patients with a variety of Interstitial Lung Diseases (ILDs).
Stanford Interstitial Lung Disease Clinic
Started in 2004, the Stanford Interstitial Lung Disease Clinic cares for patients with a variety of ILDs, including exposure-related occupational and environmental ILDs, autoimmune/connective tissue disease ILDs secondary to Rheumatoid Arthritis, Scleroderma, Dermatomyositis, and Polymyositis, and Idiopathic ILDs such as Idiopathic Pulmonary Fibrosis (IPF), Cryptogenic Organizing Pneumonia, and Sarcoidosis. A large portion of our ILD patients have Idiopathic Pulmonary Fibrosis (IPF) which is scarring of the lung tissue due to unknown (idiopathic) causes. Approximately 250,000 people in the United States and Europe have IPF with approximately 40,000 new cases reported per year in the United States. Our program includes comprehensive care, ground-breaking scientific research, and education and support for people with ILD.
Multidisciplinary Approach for Early Diagnosis
We offer a comprehensive, individualized, multidisciplinary approach to evaluate patients with possible ILDs who present with symptoms of increasing shortness of breath and cough. Many of our patients have had a difficult and prolonged journey to establish an accurate and early diagnosis. Our group includes our expert colleagues in Rheumatology, Gastroenterology, Pathology, Radiology, Interventional Pulmonology, Thoracic Surgery and Lung Transplantation in order to identify the specific type of ILD and to develop an individualized treatment plan. Patients are reviewed weekly at our Multidisciplinary Interstitial Lung Disease conference to establish a diagnosis and treatment plan based on consensus of this interdisciplinary group of experts. (Read more will link to message from the Chief)
Upcoming Events
Stanford ILD Monthly Support Group
Virtual- first Monday of every month, 11:30am -1pm.
- Feb 3, 2025: Understanding Your Bloodwork Results
- Mar 3, 2025: Pulmonary Rehabilitation: In-Person and Virtual Options
-Apr 7, 2025: Maximizing Nutrition for Patients with ILD
-May 5, 2025: Getting the ILD Diagnosis Right and Why it Matters
-Jun 2, 2025: Highlights of the American Thoracic Society International Conference
Stanford ILD CME event for Healthcare Professionals
Stanford ILD CME Program, Sept. 14, 2024 Li Ka Shing Center
Our Stanford ILD team hosted a very successful CME day "Understanding Genetic Contributors to Interstitial Lung Disease (ILD)" with Christine Kim Garcia, MD, PhD as the keynote speaker from Columbia University who addressed the current state and future directions of familial pulmonary fibrosis (FPF). The symposium aimed to improve the delivery of early, appropriate, and evidence-based care to the patient and family members with FPF and review current available genetic testing.
A team of multidisciplinary experts addressed genetics's role in diagnosing ILDs, including the increased risks and comorbidities associated with a diagnosis of FPF. Other topics included drug development for a genetic telomeropathy, screening and testing for familial ILD, liver, bone marrow and other organ dysfunction in telomeropathy-related ILD, and outcomes and consideration for lung transplant for patients with familial ILD.
Announcements
New Clinical Trials Open to Enrollment
Stanford’s ILD program includes a robust clinical research program. We have recently opened new clinical trials to enrollment for patients with Idiopathic Pulmonary Fibrosis (IPF) and also to patients with Hypersensitivity Pneumonitis (HP), Connective Tissue Disease (CTD), smoking-related ILDs, and unclassifiable fibrotic ILDs. The majority of our clinical trials allow, but do not require, participants to be on concurrent antifibrotic therapy. Investigational interventions include oral and inhaled investigational therapies for ILD.
Highlighted Publications
Bexotegrast Shows Dose-dependent Integrin αvβ6 Receptor Occupancy inLungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial
Mooney, et al, 2024, AnnalsATS; 22:265